Blood IgE and Eosinophils are not Reliable Predictors of Nasal Tissue Eosinophils in Chronic Rhinosinusitis with Nasal Polyposis.

 Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory condition of the paranasal sinuses that is mainly associated with type-2 inflammation. Immunoglobulin E (IgE) and eosinophils in blood and nasal tissue have been suggested as biomarkers for the prognosis and severity of CRSwNP as well as indications for biological treatment.  The present study aims to assess the relationships between blood IgE concentration, blood eosinophil count, and nasal polyp eosinophil count in CRSwNP patients.

Nasal irrigation solution is less cytotoxic to nasal epithelial cells than nasal spray.

Background: Recent studies have demonstrated that corticosteroid delivered by nasal irrigation is superior to nasal spray in the treatment of chronic rhinosinusitis patients who have undergone sinus surgery. However, the local cytotoxicity of both delivery methods has not been previously evaluated. In this study we aimed to evaluate the cytotoxicity of corticosteroid prepared nasal irrigation solution and commercially available corticosteroid nasal spray.

Short Cilia, Immunodeficiency, and Cystic Fibrosis in a Mother-Daughter Pair.

Patients with chronic rhinosinusitis (CRS) that is refractory to maximal medical and surgical therapy should be evaluated for other primary conditions. Cystic fibrosis (CF), primary immunodeficiency (PID), and primary ciliary dyskinesia (PCD) are potential risk factors for refractory CRS. These conditions present with variable disease severity and diagnosis may be delayed into adulthood.

Comparison between upper and lower airway microbiome profiles in chronic rhinosinusitis patients.

Background: Dysregulation of the airway microbiota is thought to contribute to airway inflammation in both chronic rhinosinusitis (CRS) and asthma. However, the relationship between the upper and lower airway microbiome remains unclear.

Methods: Sinus and lung brushes were collected from 29 CRS participants undergoing sinus surgery.

Real-World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps.

Objective: To investigate the frequency and nature of adverse events related to type 2 biologic use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), including dupilumab and mepolizumab.

Methods: This is a single-institution retrospective study of real-world patient data. Patients were included if they have a diagnosis of CRSwNP, have undergone at least one endoscopic sinus surgery, and have taken at least two doses of dupilumab or mepolizumab between January 1, 2016, and July 1, 2023.